TNF and type 2 diabetes mellitus: Low sTWEAK concentrations were associated with more inadequate cardiometabolic risk in patients with type 2 diabetes and obesity, and this can be explained by the ability of sTWEAK to antagonize in vitro TNF-α activity22.